Free Trial
→ Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:IMVT

Immunovant Q1 2026 Earnings Report

Immunovant logo
$27.22 -1.45 (-5.06%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$26.93 -0.29 (-1.07%)
As of 05/7/2026 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immunovant EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$0.60

Immunovant Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunovant Announcement Details

Quarter
Q1 2026
Date
8/11/2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunovant's Q4 2026 earnings is estimated for Thursday, June 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 29, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunovant's Q1 2026 Press ReleasePress Release
(8-K)
Immunovant's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Immunovant Earnings Headlines

Immunovant (NASDAQ:IMVT) Director Sells $67,979.34 in Stock
May 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30757448
Immunovant: Best-In-Class Ambitions, Still Unproven
April 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891979-immunovant-stock-best-in-class-ambitions-still-unproven
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
 |  Reagan Gold Group (Ad)
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
April 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4888163-immunovant-inc-imvt-discusses-brepocitinib-program-expansion-and-batoclimab-phase-iii-data
Immunovant's treatment for eye disease fails in late-stage trials
April 2, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/immunovants-treatment-for-eye-disease-fails-in-late-stage-trials/ar-AA201I8U
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow
April 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4888164-immunovant-inc-imvt-discusses-brepocitinib-program-expansion-and-batoclimab-phase-iii-data
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT) Inc. is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG. Efgartigimod is being evaluated in late-stage clinical trials for generalized myasthenia gravis and other indications, and has demonstrated the potential to provide rapid and durable reductions in pathogenic IgG levels. In addition to efgartigimod, Immunovant is advancing a pipeline of next-generation FcRn-targeted monoclonal antibodies designed to address a range of antibody-mediated diseases.

Founded in 2017 as a spin-out of Roivant Sciences, Immunovant is headquartered in New York, with research and development activities spanning North America and Europe. The company’s clinical programs involve global trial sites across key regions, and its leadership team comprises experienced executives and scientists with deep expertise in immunology and biologics development. Immunovant continues to collaborate with academic institutions and strategic partners to advance its FcRn-focused platform toward regulatory approval and commercial readiness.

View Immunovant Profile
Earnings Tools